

해외 바이오의약품 임상 현황 ('23년 8월 5주)

한국바이오의약품협회, 2023.09.06.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2023.08.28.~2023.09.03.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 89건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05987332	IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	Drug: IDE196 Drug: Crizotinib Drug: Pembrolizumab Drug: Ipilimumab Drug: Nivolumab Drug: Dacarbazine	IDEAYA Biosciences	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05987332
NCT05687721	Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer	Drug: copanlisib Drug: Avelumab	VA Office of Research and Development Bayer	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05687721
NCT05559879	Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma	Drug: Cabo + Dostarlimab	University of Alabama at Birmingham	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05559879
NCT05114837	Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL	Drug: allogeneic CAR19 regulatory T cells (CAR19-tTreg) Drug: Fludarabine Drug: Cyclophosphamide	Masonic Cancer Center, University of Minnesota	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05114837
NCT04864522	Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma	Drug: SLAMF7 FPBMC	University of Virginia	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04864522
NCT04798716	The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19	Drug: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8) Drug: MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8) Drug: MSC-exosomes delivered intravenously every other day (8:8:8)	AVEM HealthCare	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04798716
NCT04129515	NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis	Device: NovoTTF-200A Drug: Pembrolizumab	Brown University NovoCure Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04129515
NCT06016179	Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer	Drug: Tocilizumab	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06016179
NCT06015893	Semaglutide Therapy for Alcohol Reduction (STAR)	Behavioral: Take Control Drug: Semaglutide	National Institute on Drug Abuse (NIDA) National Institutes of Health Clinical Center (CC)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06015893
NCT06005818	Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)	Drug: Pembrolizumab injection	University of Alabama at Birmingham	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06005818
NCT06005012	Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM	Drug: Semaglutide Drug: Placebo	University of California, San Diego	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06005012

해외 바이오의약품 임상 현황 ('23년 8월 5주)

한국바이오의약품협회, 2023.09.06.

○ 미국 89건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06003101	Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies	Biological: Bone marrow aspirate concentrate (BMAC) Procedure: Control	Massachusetts General Hospital	Phase 3	
NCT06003049	A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD	Drug: OnabotulinumtoxinA Other: Placebo	RMW Testing	Phase 2	
NCT06001853	Allogeneic BM-MSC's in Patients With Lumbar Facet Arthropathy	Drug: BM-MSC injection Drug: DMSO Injection	Mayo Clinic	Phase 2	
NCT05994235	Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma	Drug: Mosunetuzumab Drug: Tazemetostat Pill	Weill Medical College of Cornell University Epizyme, Inc. Genentech, Inc.	Phase 2	
NCT05981209	Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies	Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Drug: Dexamethasone Procedure: Echocardiography Biological: Elotuzumab Procedure: Magnetic Resonance Imaging Biological: Mezigdomide Procedure: X-Ray Imaging	Abdullah Khan Ohio State University Comprehensive Cancer Center	Phase 1	
NCT05977907	Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).	Drug: Pembrolizumab Drug: IO102-103	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins IO Biotech Merck Sharp & Dohme LLC	Phase 2	
NCT05964868	Efficacy of Liposomal Bupivacaine Post Septorhinoplasty	Drug: Liposomal Bupivacaine Drug: 0.25% bupivacaine with 1:200,000 epinephrine Other: Placebo - Saline solution	Jessyka Lighthall Milton S. Hershey Medical Center	Phase 3	
NCT05954871	Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer	Drug: GDC-1971 Drug: Osimertinib Drug: Cetuximab	Genentech, Inc.	Phase 1	
NCT05947071	High vs.Standard Dose Influenza Vaccine in Pediatric SOT Recipients	Biological: Standard Dose Quadrivalent Inactivated Influenza Vaccine Biological: High Dose Quadrivalent Inactivated Influenza Vaccine	Vanderbilt University Medical Center Children's Hospital Medical Center, Cincinnati Lucile Packard Children's Hospital University of Pittsburgh Ann & Robert H Lurie Children's Hospital of Chicago 등	Phase 2	
NCT05931393	Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC)	Drug: Cabozantinib 80 MG Drug: Cabozantinib 40MG Tab Drug: Nivolumab	University of Texas Southwestern Medical Center Exelixis	Phase 2	
NCT05928806	Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial	Drug: Botensilimab Drug: Balstilimab Drug: Ipilimumab Drug: Nivolumab	Michael B. Atkins, MD Agenus Inc. Georgetown University Hoosier Cancer Research Network	Phase 2	

해외 바이오의약품 임상 현황 ('23년 8월 5주)

한국바이오의약품협회, 2023.09.06.

○ 미국 89건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05913388	GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma	Drug: GB1211 Drug: Pembrolizumab Drug: Placebo	Providence Health & Services Providence Cancer Center Providence Cancer Center, Earle A. Chiles Research Institute Galecto Biotech AB	Phase 2	
NCT05911997	MTC Versus FMT in for RCDI	Drug: MTC 01 Drug: Fecal Microbiota Transplantation (FMT)	Icahn School of Medicine at Mount Sinai National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1	
NCT05904886	A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)	Drug: Atezolizumab Drug: Bevacizumab Drug: Tiragolumab Other: Placebo	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3	
NCT05854966	CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)	Drug: CPI 613 Drug: Metformin Biological: Blood draws Procedure: Bone marrow biopsy	Wake Forest University Health Sciences National Cancer Institute (NCI) Cornerstone Pharmaceuticals	Phase 2	
NCT05854498	Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer	Drug: Liposomal irinotecan Drug: TAS102 Drug: Bevacizumab	University of Wisconsin, Madison Ipsen	Phase 2	
NCT05852574	CP101 for the Treatment of Ulcerative Colitis	Drug: CP-101 Drug: CP-101 + Placebo	Brigham and Women's Hospital	Phase 1	
NCT05847569	Alternate Doses and Dosing Schedules of Belantamab Mafodotin for the Treatment of Triple-Class Recurrent and/or Refractory Multiple Myeloma	Biological: Belantamab Mafodotin Procedure: Biospecimen Collection Procedure: Bone Marrow Aspirate Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography	Mayo Clinic	Phase 2	
NCT05833867	Adaptive RADIation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer	Drug: Sacituzumab govitecan Radiation: Adaptive Radiotherapy	Omar Mian Varian Inc Gilead Sciences Case Comprehensive Cancer Center	Phase 1	
NCT05806814	Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer	Biological: Sipuleucel-T	University of Oklahoma Dendreon	Phase 1	
NCT05797233	Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies	Biological: Anti-CD19 and anti-CD20 bicistronic CAR T- cells Drug: Cyclophosphamide Drug: Fludarabine	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 1	
NCT05776914	Fecal Microbiota Transplantation for IBS	Biological: Donor Fecal Microbiota Transplantation Biological: Autologous Fecal Microbiota Transplantation	Madhusudan (Madhu) Grover, MBBS Mayo Clinic	Phase 2	
NCT05763667	Pilot: Intraoperative TAP Block and Post-operative Pain Control for Minimally Invasive Hysterectomy	Drug: Liposomal bupivacaine Drug: Bupivacain	Tufts Medical Center	Phase 3	

해외 바이오의약품 임상 현황 ('23년 8월 5주)

한국바이오의약품협회, 2023.09.06.

○ 미국 89건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05761951	Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer	Drug: DKN-01 Drug: Pembrolizumab	M.D. Anderson Cancer Center Leap Therapeutics, Inc. Merck Sharp & Dohme LLC National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05761951
NCT05741164	Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Pembrolizumab Drug: Propranolol Other: Questionnaire Administration	Roswell Park Cancer Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05741164
NCT05724134	Pancreatic Clamp in NAFLD	Drug: Insulin human Drug: Octreotide Acetate Drug: Glucagon Drug: Growth Hormone, Human Other: [6,6-2H2] D-glucose Drug: 20% D-glucose (aq) Dietary Supplement: BOOST Plus Device: Harvard Apparatus PHD ULTRA CP syringe pump Device: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer	Columbia University Albert Einstein College of Medicine National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05724134
NCT05707702	Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia	Biological: Probiotic oral lozenges Other: Standard of care for oral dysplasia	Boston Medical Center University of Alabama at Birmingham	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05707702
NCT05695196	Parent-to-Child Nasal Microbiota Transplant to Promote Colonization Resistance to Staphylococcus Aureus	Biological: nasal microbiota transplant (NMT) Biological: Placebo	Johns Hopkins University National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05695196
NCT05672355	A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia	Procedure: Biospecimen Collection Biological: mRNA COVID-19 Vaccine Biological: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05672355
NCT05664126	Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation	Drug: VST infusion Device: CliniMACS	St. Jude Children's Research Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05664126
NCT05664113	Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).	Drug: Fecal microbiota transplant (FMT)	St. Jude Children's Research Hospital	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05664113
NCT05655949	Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio	Drug: Gemcitabine Drug: Cisplatin Drug: Durvalumab Radiation: Yttrium-90	Beth Israel Deaconess Medical Center AstraZeneca Sirtex Medical Dana-Farber Cancer Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05655949
NCT05632315	PMT for MDRO Decolonization	Drug: PMT	University of Pennsylvania	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05632315
NCT05627232	Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	Drug: Tazemetostat Drug: Liposome-encapsulated Daunorubicin-Cytarabine Procedure: Bone Marrow Aspiration and Biopsy Procedure: Biospecimen Collection Drug: Palbociclib	Thomas Jefferson University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05627232
NCT05618925	Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma	Drug: N803 Biological: CD19t-haNK suspension Drug: Cyclophosphamide Drug: Fludarabine Drug: Rituximab	ImmunityBio, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05618925

해외 바이오의약품 임상 현황 ('23년 8월 5주)

한국바이오의약품협회, 2023.09.06.

○ 미국 89건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05604560	A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer	Drug: Tislelizumab Drug: SX-682	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins BeiGene Syntrix Biosystems, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05604560
NCT05518032	Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)	Procedure: Biopsy Biological: Pembrolizumab Biological: Therapeutic Autologous Dendritic Cells	Roswell Park Cancer Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05518032
NCT05424003	Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant	Drug: Semaglutide Pen Injector Drug: Placebo	Virginia Commonwealth University Novo Nordisk A/S	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05424003
NCT05400603	Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma	Combination Product: Ex Vivo Expanded Allogeneic $\gamma\delta$ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate	Emory University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05400603
NCT05286255	Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias	Biological: Allogeneic Mesenchymal Stromal Cells	Medical University of South Carolina Pandorum International, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05286255
NCT05029336	Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases	Biological: Depletion of CD3/CD19 in an autologous stem cell transplant	Stephan Grupp MD PhD Children's Hospital of Philadelphia	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05029336
NCT04280471	Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease	Drug: Fecal Microbiota Transplantation Capsule	Jonsson Comprehensive Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04280471
NCT04093323	Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells Drug: Celecoxib Drug: PD-1 Ligand Inhibitor Drug: PD1 Inhibitor Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04093323
NCT03988283	Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors	Biological: Personalized neoantigen DNA vaccine Device: Ichor TDS-IM v2.0 Procedure: Peripheral blood draw	Washington University School of Medicine Children's Discovery Institute	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT03988283
NCT05973487	A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors	Biological: TSC-204-A0201 Biological: TSC-204-C0702 Biological: TSC-200-A0201 Biological: TSC-204-A0201 + TSC-204-C0702 Biological: TSC-204-A0201 + TSC-200-A0201	TScan Therapeutics, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05973487
NCT05967351	A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparovec (SRP-9001) in a Previous Clinical Study	Genetic: delandistrogene moxeparovec	Sarepta Therapeutics, Inc. Hoffmann-La Roche	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05967351
NCT05656235	Renal Retention in High Grade Upper Tract Urothelial Cancer	Drug: Enfortumab vedotin Drug: Pembrolizumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Astellas Pharma Inc Seagen Inc Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05656235
NCT05354544	Evaluating Autologous Stromal Vascular Fraction in Subjects With Vocal Fold Scar	Biological: Autologous adipose derived SVF	Shane A. Shapiro Mayo Clinic	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05354544

해외 바이오의약품 임상 현황 ('23년 8월 5주)

한국바이오의약품협회, 2023.09.06.

○ 미국 89건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05291676	Systems Investigation of Vaccine Responses in Aging and Frailty	Biological: Fluzone Biological: Fluad	Yale University National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05291676
NCT04563520	SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis	Drug: aPCC-emicizumab Drug: FEIBA Drug: rFVIIa	Emory University Takeda Pharmaceuticals North America, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT04563520
NCT03258658	Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures	Biological: Autologous Engineered Urethral Construct	Wake Forest University Health Sciences United States Department of Defense	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT03258658
NCT05906953	A Safety and Efficacy Study of HG004 in Subjects With Leber Congenital Amaurosis	Drug: HG004	HuidaGene Therapeutics Co., Ltd. Cholgene Therapeutics, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05906953
NCT06003465	A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices	Drug: LY3437943 Device: Test Device: Reference	Eli Lilly and Company	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06003465
NCT05846789	Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers	Drug: Carboplatin Drug: Tocilizumab	Kathy Miller Genentech, Inc. Indiana University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05846789
NCT05730712	Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer, TraPPER Study	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Echocardiography Drug: Enzalutamide Drug: Hyaluronidase-zzxf Pertuzumab Trastuzumab Procedure: Magnetic Resonance Imaging Other: Questionnaire Administration	Mayo Clinic	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05730712
NCT05715229	Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy	Drug: Nivolumab Drug: Ipilimumab Drug: Carboplatin Drug: Paclitaxel Drug: Pemetrexed	Hackensack Meridian Health MedSIR	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05715229
NCT05479045	A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients	Biological: NY-ESO-1 Peptide vaccine Drug: Nivolumab	Georgetown University United States Department of Defense Bristol-Myers Squibb	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05479045
NCT05938465	Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)	Biological: EXE-346 Other: Placebo	Exegi Pharma, LLC The Emmes Company, LLC	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05938465
NCT05067257	Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer	Drug: Resiniferatoxin Drug: Placebo	Sorrento Therapeutics, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05067257
NCT05937152	A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy	Drug: Eptinezumab Drug: Placebo	Mayo Clinic	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05937152

해외 바이오의약품 임상 현황 ('23년 8월 5주)

한국바이오의약품협회, 2023.09.06.

○ 미국 89건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05896163	A Study to Learn About the Effects of Two Study Medicines (Maplirpcept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.	Drug: maplirpcept (PF-07901801) Drug: Glofitamab Drug: Obinutuzumab	Pfizer Hoffmann-La Roche	Phase 1 Phase 2	
NCT04373941	Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia	Drug: Filgrastim	Holterman, Ai-Xuan, M.D. T Rose Clinical, Inc. Big Leap Research Prometheus USA	Phase 2	
NCT05682443	ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC	Drug: ONC-392 Drug: lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.	OncoC4, Inc. Prostate Cancer Clinical Trials Consortium	Phase 2	
NCT05925127	Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines	Biological: NVX-CoV2373 (5µg) Biological: NVX-CoV2601 (5µg) Biological: NVX-CoV2601(5µg) Biological: NVX-CoV2601 (35µg) Biological: NVX-CoV2601(35µg) Biological: NVX-CoV2601(50µg) Biological: Bivalent BA.4/5	Novavax	Phase 2 Phase 3	
NCT05642455	SPEARHEAD-3 Pediatric Study	Genetic: Afamitresgene autoleucel	Adaptimmune	Phase 1 Phase 2	
NCT05941507	Phase 1/2 Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors	Drug: LCB84 Drug: Anti-PD-1 monoclonal antibody	LegoChem Biosciences, Inc. AntibodyChem Biosciences, Inc.	Phase 1 Phase 2	
NCT05931367	A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee	Drug: Retatrutide Drug: Placebo	Eli Lilly and Company	Phase 3	
NCT05911295	Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2	Drug: disitamab vedotin Drug: pembrolizumab Drug: gemcitabine Drug: cisplatin Drug: carboplatin	Seagen Inc. RemeGen Co., Ltd. Merck Sharp & Dohme LLC	Phase 3	
NCT05890352	Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment	Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Lenalidomide Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography Other: Quality-of-Life Assessment Other: Questionnaire Administration Biological: Tafasitamab Drug: Tazemetostat Drug: Zanubrutinib	SWOG Cancer Research Network National Cancer Institute (NCI) BeiGene Ipsen Incyte Corporation	Phase 2	
NCT05836259	Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM	Genetic: TN-201	Tenaya Therapeutics	Phase 1	
NCT05997264	Anthrax AV7909 Boost Evaluation Study	Biological: AV7909 Full Dose (0.5 mL) Biological: AV7909 Half Dose (0.25 mL)	Biomedical Advanced Research and Development Authority Rho Federal Systems Division, Inc. ICON plc	Phase 2	
NCT05722938	Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)	Drug: Trimodulin Drug: Placebo (human albumin 1%)	Biotest	Phase 3	

해외 바이오의약품 임상 현황 ('23년 8월 5주)

한국바이오의약품협회, 2023.09.06.

○ 미국 89건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05951959	A Study of Acabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)	Drug: Acabrutinib Drug: Venetoclax Drug: Rituximab	AstraZeneca	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05951959
NCT05063565	TheraSphere With Durvalumab and Tremelimumab for HCC	Device: TheraSphere Y-90 glass microsphere therapy Drug: Durvalumab (Imfinzi) immunotherapy Drug: Tremelimumab immunotherapy	Boston Scientific Corporation Biocompatibles UK Ltd	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05063565
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598
NCT05909995	Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors	Drug: INCB 99280 with Ipilimumab	Incyte Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05909995
NCT05891171	Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers	Drug: AB598 Drug: Zimberelimab Drug: Carboplatin Drug: Pemetrexed Drug: Fluorouracil Drug: Leucovorin Drug: Oxaliplatin	Arcus Biosciences, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05891171
NCT06023641	Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease	Drug: Vincristine Drug: Dactinomycin Drug: Cyclophosphamide Procedure: Surgical Resection Procedure: Proton beam radiation or external beam radiation or brachytherapy Drug: Liposomal irinotecan Drug: Vinorelbine Drug: Temozolomide Drug: Filgrastim, peg-filgrastim	St. Jude Children's Research Hospital	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06023641

○ 영국 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06016920	Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma	Biological: VB10.16 Drug: Pembrolizumab	Nykode Therapeutics ASA Merck Sharp & Dohme LLC	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06016920
NCT05711849	Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina	Biological: Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells. Procedure: Sham bone marrow aspiration and sham cell infusion (insertion of vascular access sheath).	Barts & The London NHS Trust	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05711849
NCT05770102	DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition	Drug: Atezolizumab	Cancer Research UK University of Manchester University of Birmingham Royal Marsden NHS Foundation Trust Hoffmann-La Roche	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05770102
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598

해외 바이오의약품 임상 현황 ('23년 8월 5주)

한국바이오의약품협회, 2023.09.06.

○ 영국 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05936359
NCT05931367	A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee	Drug: Retatrutide Drug: Placebo	Eli Lilly and Company	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05931367

○ 프랑스 9건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05979831	A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome	Drug: DS-2325a Other: Placebo	Daiichi Sankyo, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05979831
NCT05888857	MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.	Drug: MEDI5752	Institut Bergonié National Cancer Institute, France AstraZeneca	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05888857
NCT03172299	Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma	Drug: Aflibercept Injection Drug: False injection	Centre Hospitalier Universitaire de Nice	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT03172299
NCT05917561	Efficacy and Tolerance of the Association of ANIFROLUMAB (300mg) IV Every Four Weeks and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo	Drug: Anifrolumab Infusion Product Drug: Placebo	University Hospital, Bordeaux AstraZeneca	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05917561
NCT05821231	Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma	Combination Product: SBRT + MEDI5752	Institut Claudius Regaud National Cancer Institute, France AstraZeneca	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05821231
NCT05856695	A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)	Drug: Carboplatin + Paclitaxel + Durvalumab	Intergroupe Francophone de Cancerologie Thoracique	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05856695
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05936359
NCT05722938	Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)	Drug: Trimodulin Drug: Placebo (human albumin 1%)	Biotest	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05722938

해외 바이오의약품 임상 현황 ('23년 8월 5주)

한국바이오의약품협회, 2023.09.06.

○ 독일 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05936359
NCT05722938	Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)	Drug: Trimodulin Drug: Placebo (human albumin 1%)	Biotest	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05722938

○ 중국 40건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06006403	Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm	Biological: CD123 targeted CAR-NK cells	Chongqing Precision Biotech Co., Ltd Shanxi Bethune Hospital	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06006403
NCT05990452	Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors	Drug: 9MW2921	Mabwell (Shanghai) Bioscience Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05990452
NCT05980481	A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer	Drug: RC48-ADC Drug: Herceptin Drug: Toripalimab Drug: Oxaliplatin injection Drug: Capecitabine	RemeGen Co., Ltd.	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05980481
NCT05978284	Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma	Biological: ZG006	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05978284
NCT05944185	Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors	Drug: αPD1-MSLN-CAR T Cells	Shanghai Cell Therapy Group Co.,Ltd Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05944185
NCT05940610	The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure	Biological: MSC-EVs	Third Affiliated Hospital, Sun Yat-Sen University	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05940610
NCT05821933	RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC	Drug: RC108	RemeGen Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05821933
NCT06019702	Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms	Biological: iNeo-Vac-R01	Sir Run Run Shaw Hospital Hangzhou Neoantigen Therapeutics Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06019702
NCT06017583	Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer	Drug: Tislelizumab Drug: Capecitabine Drug: Oxaliplatin Radiation: SIB-IMRT Radiation: IMRT	Yong Zhang,MD First Affiliated Hospital of Guangxi Medical University	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06017583
NCT06016413	Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck	Drug: Nab paclitaxel Drug: Carboplatin Drug: adelbelimumab	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06016413

해외 바이오의약품 임상 현황 ('23년 8월 5주)

한국바이오의약품협회, 2023.09.06.

○ 중국 40건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06014775	Anti-CD38 Antibody Treating Evans Syndrome	Drug: Anti-CD38 antibody Injection	Institute of Hematology & Blood Diseases Hospital	Phase 2	
NCT06008054	A Study of SI-B003 and BL-B01D1+SI-B003 in the Treatment of Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors	Drug: SI-B003 Drug: BL-B01D1	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2	
NCT06006169	A Study of BL-B01D1 and BL-B01D1+SI-B003 in the Treatment of Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Non-nasopharyngeal Carcinoma)	Drug: BL-B01D1 Drug: SI-B003	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2	
NCT05998122	Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study	Other: nCRT → (CapeOX+Sintilimab)× 6 → Surgery/W&W	The First Hospital of Jilin University	Phase 2	
NCT05997576	A Study of TG103 Injection in Non-diabetic Overweight or Obesity	Drug: TG103 22.5 mg Drug: Placebo	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	Phase 3	
NCT05990803	A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in the Treatment of Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies	Drug: BL-B01D1 Drug: SI-B003	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2	
NCT05988372	Sulfatinib and Serplulimab Combined With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer : A Single-arm, Phase II Study(SAGE)	Drug: Sulfatinib Drug: Serplulimab Drug: Albumin-paclitaxel Drug: Gemcitabine	Sun Yat-sen University	Phase 2	
NCT05984303	Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1b)	Biological: Human Umbilical Cord-derived Mesenchymal Stem Cells	Beijing 302 Hospital Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China	Phase 1	
NCT05983094	Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer	Drug: Utidelone Drug: Carboplatin Drug: Epirubicin Drug: Trastuzumab Drug: Pertuzumab	Cancer Institute and Hospital, Chinese Academy of Medical Sciences Chinese Academy of Medical Sciences Cancer Hospital, Shanxi Center Chinese Academy of Medical Sciences Cancer Hospital, Shenzhen Center First Affiliated Hospital of China Medical University	Phase 2	
NCT05980689	Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer	Drug: AK104 Drug: Capecitabine Radiation: Neoadjuvant Radiotherapy	Sun Yat-sen University Akeso Haplox Biotechnology Co., Ltd.	Phase 2	
NCT05975151	Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer	Drug: Pseudomonas aeruginosa	Qilu Hospital of Shandong University	Phase 2	

해외 바이오의약품 임상 현황 ('23년 8월 5주)

한국바이오의약품협회, 2023.09.06.

○ 중국 40건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05954897	Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma	Drug: Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC	Guangdong Provincial People's Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05954897
NCT05910970	Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation	Drug: Adjuvant tislelizumab plus lenvatinib Drug: Adjuvant tislelizumab	Guangxi Medical University	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05910970
NCT05820906	Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer	Drug: Cadonilimab+Regorafenib+GC	Tianjin Medical University Cancer Institute and Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05820906
NCT05481476	Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer	Drug: Surufatinib Drug: Sintilimab Drug: AG	Sun Yat-sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05481476
NCT06006390	CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors	Biological: CEA-targeted CAR-T cells	Chongqing Precision Biotech Co., Ltd Shanxi Bethune Hospital	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06006390
NCT05976568	A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma	Drug: QL1706 Drug: Bevacizumab Drug: Oxaliplatin injection Drug: Capecitabine Drug: Sintilimab	Qilu Pharmaceutical Co., Ltd.	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05976568
NCT06006741	Universal CAR-T Cells Targeting Multiple Myeloma	Biological: MM-specific universal CAR T cells	Shenzhen Geno-Immune Medical Institute The Second Affiliated Hospital of Hainan Medical University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06006741
NCT05973149	Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer	Drug: QLH12016	Qilu Pharmaceutical Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05973149
NCT05906953	A Safety and Efficacy Study of HG004 in Subjects With Leber Congenital Amaurosis	Drug: HG004	HuidaGene Therapeutics Co., Ltd. Cholgene Therapeutics, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05906953
NCT06016062	A Study of RC148 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors	Drug: RC148	RemeGen Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06016062
NCT06015568	Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation	Drug: MCLA-129: 1500mg or 2000mg IV Q2W Drug: Befotertinib: 75 mg or 100 mg Po QD	Betta Pharmaceuticals Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06015568
NCT06014073	TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL	Biological: TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T) Drug: Fludarabine Drug: Cyclophosphamide	Chinese PLA General Hospital Peking University EdiGene Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06014073
NCT05995041	Universal CAR-T Cells Targeting AML	Biological: CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells	Shenzhen Geno-Immune Medical Institute The Second Affiliated Hospital of Hainan Medical University Beijing Jingdu Children's Hospital	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05995041
NCT05995028	Universal 4SCAR7U Targeting CD7-positive Malignancies	Biological: Universal CD7-specific CAR gene-engineered T cells	Shenzhen Geno-Immune Medical Institute Beijing Jingdu Children's Hospital The Second Affiliated Hospital of Hainan Medical University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05995028

해외 바이오의약품 임상 현황 ('23년 8월 5주)

한국바이오의약품협회, 2023.09.06.

○ 중국 40건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05995015	4SCAR19U T Cells Targeting B Cell Malignancies	Biological: Universal CD19-specific CAR gene-engineered T cells	Shenzhen Geno-Immune Medical Institute The Second Affiliated Hospital of Hainan Medical University Beijing Jingdu Children's Hospital	Phase 1	
NCT05850546	Rituximab in the First Episode of Paediatric Nephrotic Syndrome	Drug: Rituximab Drug: Corticosteroid	Children's Hospital of Fudan University Shanghai Shen Kang Hospital Development Center Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Children's Medical Center Shanghai Children's Hospital	Phase 3	
NCT06010901	A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection 罍Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.	Drug: TQB2618 injection Drug: Penpulimab injection Drug: Anlotinib hydrochloride capsules	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1	
NCT06008405	Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy	Drug: TQB2928 Injection + Azacitidine for injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1	
NCT05931367	A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee	Drug: Retatrutide Drug: Placebo	Eli Lilly and Company	Phase 3	

○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05896163	A Study to Learn About the Effects of Two Study Medicines (Maplirpcept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.	Drug: maplirpcept (PF-07901801) Drug: Glofitamab Drug: Obinutuzumab	Pfizer Hoffmann-La Roche	Phase 1 Phase 2	
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	